Nektar Therapeutics
$67.38
$0.74 (+1.11%)
$65.85Day Range$67.65
Key Statistics
Market Cap
$2.28B
Shares Outstanding
34.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 3, 1994
Round Lot
100
Locale
US
Trading Data
Day Open
$67.00
Day High
$67.65
Day Low
$65.85
Volume
986.1K
VWAP
$66.98
Prev Close
$66.64
Transactions
--
Acc. Volume
--
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
PHARMACEUTICAL PREPARATIONSSIC 283463 employees455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158(415) 482-5300IPO May 3, 1994US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000906709
- Composite FIGI
- BBG000BHCYJ1
- Share Class FIGI
- BBG001S7RDK1
- Ticker Root
- NKTR
- SIC Code
- 2834
About Nektar Therapeutics (NKTR) Stock
Nektar Therapeutics (NKTR) closed the 2026-09-16 session at $67.38, up 1.11% versus the previous close (+0.74). The stock opened at $67.00 and traded between $65.85 and $67.65 during that session. Session trading volume was 986K shares. The volume-weighted average price (VWAP) is $66.98.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Nektar Therapeutics has a market capitalization of $2.28 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. NKTR is listed on the XNAS exchange. The company employs approximately 63 people. Nektar Therapeutics is headquartered in SAN FRANCISCO, CA. The recorded listing date is 1994-05-03.
On this page you can find market NKTR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.